FindTrial
Sign In

The combination of DC-CIK immunotherapy and interventional therapy for the treatment of late stage liver cancer

The combination of DC-CIK immunotherapy and interventional therapy for the treatment of late stage liver cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OPN-14005604
Enrollment
Unknown
Registered
2014-12-04
Start date
2011-01-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

late stage liver cancer

Interventions

A:TACE combined with DC-CIK
B:TACE alone

Sponsors

The Second Affiliated Hospital of Guangzhou Medicine University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
39 Years to 77 Years

Inclusion criteria

Inclusion criteria: The inclusion criteria: (1) 18 years of age or older, male or female; (2) were diagnosed with advanced primary liver cancer, operation treatment; (3) clinical stage IV; (4) there must be at least one measurable disease, according to the evaluation standard of curative effect of solid tumor (RESIST version 1.1); (5) physical status of PS 0-2; (6) the expected survival time than March; (7) laboratory examination to meet the following criteria: A. bone marrow function: blood neutrophil absolute count is greater than or equal to 1.5*10^9/L (ANC), platelet (PLT) = 100*10^9/L, hemoglobin (HB) = 90g/L; B.: liver function, serum total bilirubin (STB), total bilirubin (CB) less than or equal to the upper limit of normal (ULN) *1.5, alanine aminotransferase (ALT), aspartate aminotransferase (AST) = ULN*2.5 (without liver metastasis, or less than or equal to ULN*5 (lower) with liver metastasis when); C. renal function: serum creatinine (Cr) = ULN, endogenous creatinine clearance rate (Ccr) = 60ml/min (calculated by Cockcroft-Gault formula, see Appendix 2); (8) during the period of research and treatment within six months of contraceptive and non lactation (9) patients voluntarily signed the informed consent.

Exclusion criteria

Exclusion criteria: (1) arrhythmias, congestive heart failure, or severe coronary artery disease; (2) pregnant and lactating women; (3) in patients with severe autoimmune disease; (4) the long-term use or are using immunosuppressive patients; (5) for the treatment of all biological reagent allergy, such as IL-2; (6) coagulation dysfunction; (7) the researchers think that the appropriate into the group of cases.

Design outcomes

Primary

MeasureTime frame
cytokine levels;lymphocyte subsets;Progress Free Survival;Overall survival;Quality of Life;Safety;—

Countries

China

Contacts

Public ContactPing Xue
gyeyxueping@163.com+86 18926298142

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026